September 2016
Volume 57, Issue 12
Open Access
ARVO Annual Meeting Abstract  |   September 2016
Long-term Outcomes of Rituximab therapy in patients with non-infectious posterior uveitis refractory to conventional immunosuppressive therapy
Author Affiliations & Notes
  • Lina Ma
    Massachusetts Eye Research and Surgery Institution , Waltham, Massachusetts, United States
    Ocular Immunology and Uveitis Fundation, Walthma, Massachusetts, United States
  • Andres Lasave
    Massachusetts Eye Research and Surgery Institution , Waltham, Massachusetts, United States
    Ocular Immunology and Uveitis Fundation, Walthma, Massachusetts, United States
  • Caiyun You
    Massachusetts Eye Research and Surgery Institution , Waltham, Massachusetts, United States
    Ocular Immunology and Uveitis Fundation, Walthma, Massachusetts, United States
  • khawla abusamra
    Massachusetts Eye Research and Surgery Institution , Waltham, Massachusetts, United States
    Ocular Immunology and Uveitis Fundation, Walthma, Massachusetts, United States
  • C. Stephen Foster
    Massachusetts Eye Research and Surgery Institution , Waltham, Massachusetts, United States
    Ocular Immunology and Uveitis Fundation, Walthma, Massachusetts, United States
  • Neel Lamba
    Massachusetts Eye Research and Surgery Institution , Waltham, Massachusetts, United States
    Ocular Immunology and Uveitis Fundation, Walthma, Massachusetts, United States
  • Manuel Navarro
    Massachusetts Eye Research and Surgery Institution , Waltham, Massachusetts, United States
    Ocular Immunology and Uveitis Fundation, Walthma, Massachusetts, United States
  • Footnotes
    Commercial Relationships   Lina Ma, None; Andres Lasave, None; Caiyun You, None; khawla abusamra, None; C. Stephen Foster , None; Neel Lamba, None; Manuel Navarro, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science September 2016, Vol.57, 1862. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Lina Ma, Andres Lasave, Caiyun You, khawla abusamra, C. Stephen Foster, Neel Lamba, Manuel Navarro; Long-term Outcomes of Rituximab therapy in patients with non-infectious posterior uveitis refractory to conventional immunosuppressive therapy. Invest. Ophthalmol. Vis. Sci. 2016;57(12):1862.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Posterior uveitis is a severe sight threatening eye disease and the treatment is challenging. We performed a retrospective study to assess long-term effectiveness of Rituximab (RTX) therapy in the treatment of patients with refractory non-infectious posterior uveitis.

Methods : A chart review identified 11 posterior uveitis patients (21 eyes) that were treated with RTX intravenous infusions who presented at the Massachusetts Eye Research and Surgery Institute between 2010 and 2015. RTX was administered as a dose regimen of 375 mg/m2 intravenous infusion weekly for 8 consecutive weeks, and thereafter, monthly for 4 consecutive months; reassess for weaning or continuing monthly infusion was then performed. Main outcome measures of the treatment response were fluorescein angiography (FA) evidence of disc or vascular staining at 6, 12, 18 and 24 months and best-corrected visual acuity (BCVA). Secondary outcome measure was drug-related adverse events.

Results : Eleven patients (21 eyes) with refractory posterior uveitis treated with intravenous RTX were included. All the eligible subjects received several combinations of one or more disease-modifying antirheumatic drug (DMARDs) and at least one anti-TNF drug before the RTX therapy. Nine (81.8%) patients were female. Mean follow up was 29.3 ± 7.8 months. RTX was administered as complementary therapy due to prior inefficacy of other therapies in 7 (63.7%) patients and it was the only treatment in 4 (36.3%) patients who did not tolerate other drugs. Inflammation signs by FA were controlled in 9 (81.8 %) patients at the end of follow up. Baseline BCVA was 20/60 (logMAR 0.5 ± 0.1) and final BCVA was 20/30 (0.2 ± 0.1) (p=0.006). No significant side effects occurred secondary to this therapy.

Conclusions : Although randomized controlled trials are needed, the available evidence suggests the clinical use of RTX infusion in selected categories of patients with refractory chronic uveitis. RTX therapy was associated with stability and remission of recalcitrant posterior uveitis in patients who did not tolerate, had contraindications to, or did not respond to other therapies.

This is an abstract that was submitted for the 2016 ARVO Annual Meeting, held in Seattle, Wash., May 1-5, 2016.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×